Market News
Smart Trading. Simplified.
The $62.7 Billion Memory-Saving Market
15.8 million people suffer from Alzheimer's, Parkinson's or ALS. But one little-known biotech is at the forefront revolutionizing this expected $62.7 billion market.
Invest alongside Jeff Bezos, Goldman Sachs, and BlackRock in what The Economist is calling "A Boon to Humanity."
Click here to be a part of it >>>
What Is The Best FAANG Stock To Buy?
It’s no secret that Big Tech has an outsized influence on the larger market. In fact, as of July 2021, five mega-companies accounted for nearly a quarter of the S&P 500. These five include the so-called FAAMG companies: Facebook (FB) – market cap $995 billion Apple (AAPL) – market cap $2.4 trillion Amazon (AMZN) – […]
Stock Market Whiz Kid Works 1 Hour a Day. Makes Millions.
He was living with his parents. Two years later he had $5 million to play with - all because of this 1 EXTRA INCOME strategy.
To see how he did it click here.
Is General Dynamics A Good Stock To Buy?
General Dynamics Corporation [NYSE: GD] is a global aerospace and defense company, which offers a wide range of products and services, ranging from Gulfstream business jets and combat vehicles to nuclear-powered submarines and communications systems. It operates through four segments: Aerospace, Marine Systems, Combat Systems and Technologies. The company’s largest operating unit, Marine Systems, designs, […]
Small Biotech Could Soar 1,000%
There's no sector poised to deliver bigger gains in 2021 than small-cap biotech stocks.
In the past year alone...
Novavax Inc jumped from $6.26 to $270.51, a gain of 3,396%.
Aclaris Therapts jumped from $0.70 to $24.28 an increase of 1,583%.
Vaxart Inc rocketed from $0.97 to $14.94, a 1,083% jump.
Here's the next biotech we think could soar 1,000% >>>
Is Hippo Stock A Buy?
Hippo Holdings Inc. (HIPO) is an emerging, newly floated InsurTech company looking to disrupt the lucrative homeowners insurance market. Its share price took a tumble recently, falling from highs of $15 to its present value of just less than $5. The big question for investors is whether Hippo’s current price represents a quality discount for […]
The World's First $20 Trillion Drug?
One small biotech holds the key to a revolution in treating Alzheimer's. Jeff Bezos, Goldman Sachs & a Big Pharma giant have invested billions into this unknown biotech.
Our research shows that anyone who gets in by October 6th, 2021 could turn every $1,000 into $1.1 million.
Nvidia vs Facebook: Which Stock Will Rule the Omniverse?
Both Facebook and Nvidia have big plans for the omniverse: Nvidia launched its Nvidia Omniverse platform as a cloud-based platform to help 3D production workflows adopted from Pixar. Facebook is bundling its messaging and social platforms with its Oculus VR platform for the Facebook Metaverse. So, which is the better investment between Facebook, Inc (NASDAQ:FB) […]
WARNING to all American Investors
China's sneaky plan could wipe out your retirement - in a single morning.
Learn how to protect yourself here >>>
Is CuriosityStream Stock a Buy?
CuriosityStream (CURI) is a relatively new media company that was founded in 2015 by John Hendricks from the Discovery Channel. The company features factual video content, including short- and long-form video media, such as documentaries, to its subscribers. On October 15, 2020, the CuriosityStream public IPO debuted at $13 per share through a SPAC merger […]
Buy Gold & Silver with Your IRA/401(k) Using this IRS Loophole
Rollover your 401K to a precious metals IRA and protect yourself & family from inflation. From the #1 gold IRA Company, This free gold & silver IRA guide will show you how you can roll over your IRA or 401(k) into precious metals. Tax free & penalty-free into an IRA holding using a loophole the IRS doesn't want you to know!
View this email online if it doesn't display correctly. This newsletter is not financial advice. Please read our Disclaimer.
To unsubscribe from Financhill, click here.
PO Box 126
Catasauqua, PA 18032
Financhill is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of Financhill are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.
The sender of this email makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity's compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.
The content on any of Financhill websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The Financhill.com educational training program and software services are provided to improve financial understanding.
The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.
Past performance is no guarantee of future performance. This product is for educational purposes only. Practical application of the products herein are at your own risk and Financhill.com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Any trades shown are hypothetical example and do not represent actual trades. Actual results may differ. Nothing here in constitutes a recommendation respecting the particular security illustrated.
No comments:
Post a Comment